Galcanezumab Injections Reduce Episodic Migraine Headache Days Galcanezumab Injections Reduce Episodic Migraine Headache Days

Injections of the calcitonin-gene-related peptide (CGRP) monoclonal antibody galcanezumab reduce monthly headache days in patients with episodic migraine, according to results from the EVOLVE-1 phase 3 study.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news